HER-2 expression

News alerts, weekly reports and conference planners

Entrez ID:

2064

Related biomarkers:

‹

›

HER-2 expression	Gastroesophageal Cancer	HER-2 expression	Gastroesophageal Cancer	ZW25 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) ZW25 Sensitive : C3 ASCO-GI 2023 - 2wk	ZW25 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks ZW25 Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 expression	Endometrial Adenocarcinoma	HER-2 expression	Endometrial Adenocarcinoma	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : A2	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : A2
HER-2 expression	Breast Cancer	HER-2 expression	Breast Cancer	ARX788 Sensitive: B - Late Trials ARX788 Sensitive : B	ARX788 Sensitive: B - Late Trials ARX788 Sensitive : B
HER-2 expression	Biliary Tract Cancer	HER-2 expression	Biliary Tract Cancer	ZW25 Sensitive: B - Late Trials ZW25 Sensitive : B	ZW25 Sensitive: B - Late Trials ZW25 Sensitive : B
HER-2 expression	Cholangiocarcinoma	HER-2 expression	Cholangiocarcinoma	trastuzumab + lapatinib Sensitive: B - Late Trials trastuzumab + lapatinib Sensitive : B	trastuzumab + lapatinib Sensitive: B - Late Trials trastuzumab + lapatinib Sensitive : B
HER-2 expression	HER2 Positive Breast Cancer	HER-2 expression	HER2 Positive Breast Cancer	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria trastuzumab + pertuzumab Sensitive : C2	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria trastuzumab + pertuzumab Sensitive : C2
HER-2 expression	Gastric Cancer	HER-2 expression	Gastric Cancer	trastuzumab Sensitive: C2 – Inclusion Criteria trastuzumab Sensitive : C2	trastuzumab Sensitive: C2 – Inclusion Criteria trastuzumab Sensitive : C2
HER-2 expression	HER2 Positive Breast Cancer	HER-2 expression	HER2 Positive Breast Cancer	trastuzumab Sensitive: C2 – Inclusion Criteria trastuzumab Sensitive : C2	trastuzumab Sensitive: C2 – Inclusion Criteria trastuzumab Sensitive : C2
HER-2 expression	Colorectal Cancer	HER-2 expression	Colorectal Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: C2 – Inclusion Criteria fam-trastuzumab deruxtecan-nxki Sensitive : C2	fam-trastuzumab deruxtecan-nxki Sensitive: C2 – Inclusion Criteria fam-trastuzumab deruxtecan-nxki Sensitive : C2
HER-2 expression	Gastroesophageal Junction Adenocarcinoma	HER-2 expression	Gastroesophageal Junction Adenocarcinoma	fam-trastuzumab deruxtecan-nxki Sensitive: C2 – Inclusion Criteria fam-trastuzumab deruxtecan-nxki Sensitive : C2	fam-trastuzumab deruxtecan-nxki Sensitive: C2 – Inclusion Criteria fam-trastuzumab deruxtecan-nxki Sensitive : C2
HER-2 expression	Gastric Cancer	HER-2 expression	Gastric Cancer	A166 Sensitive: C2 – Inclusion Criteria A166 Sensitive : C2	A166 Sensitive: C2 – Inclusion Criteria A166 Sensitive : C2
HER-2 expression	Breast Cancer	HER-2 expression	Breast Cancer	lapatinib Sensitive: C2 – Inclusion Criteria lapatinib Sensitive : C2	lapatinib Sensitive: C2 – Inclusion Criteria lapatinib Sensitive : C2
HER-2 expression	Colorectal Cancer	HER-2 expression	Colorectal Cancer	A166 Sensitive: C2 – Inclusion Criteria A166 Sensitive : C2	A166 Sensitive: C2 – Inclusion Criteria A166 Sensitive : C2
HER-2 expression	HER2 Positive Breast Cancer	HER-2 expression	HER2 Positive Breast Cancer	A166 Sensitive: C2 – Inclusion Criteria A166 Sensitive : C2	A166 Sensitive: C2 – Inclusion Criteria A166 Sensitive : C2
HER-2 expression	HER2 Positive Breast Cancer	HER-2 expression	HER2 Positive Breast Cancer	avelumab Sensitive: C2 – Inclusion Criteria avelumab Sensitive : C2	avelumab Sensitive: C2 – Inclusion Criteria avelumab Sensitive : C2
HER-2 expression	Solid Tumor	HER-2 expression	Solid Tumor	fam-trastuzumab deruxtecan-nxki Sensitive: C2 – Inclusion Criteria fam-trastuzumab deruxtecan-nxki Sensitive : C2	fam-trastuzumab deruxtecan-nxki Sensitive: C2 – Inclusion Criteria fam-trastuzumab deruxtecan-nxki Sensitive : C2
HER-2 expression	Urothelial Cancer	HER-2 expression	Urothelial Cancer	toripalimab + disitamab vedotin Sensitive: C2 – Inclusion Criteria toripalimab + disitamab vedotin Sensitive : C2	toripalimab + disitamab vedotin Sensitive: C2 – Inclusion Criteria toripalimab + disitamab vedotin Sensitive : C2
HER-2 expression	Solid Tumor	HER-2 expression	Solid Tumor	SBT6050 Sensitive: C2 – Inclusion Criteria SBT6050 Sensitive : C2	SBT6050 Sensitive: C2 – Inclusion Criteria SBT6050 Sensitive : C2
HER-2 expression	Gastric Cancer	HER-2 expression	Gastric Cancer	AST-301 Sensitive: C2 – Inclusion Criteria AST-301 Sensitive : C2	AST-301 Sensitive: C2 – Inclusion Criteria AST-301 Sensitive : C2
HER-2 expression	Gastric Cancer	HER-2 expression	Gastric Cancer	disitamab vedotin Sensitive: C2 – Inclusion Criteria disitamab vedotin Sensitive : C2	disitamab vedotin Sensitive: C2 – Inclusion Criteria disitamab vedotin Sensitive : C2
HER-2 expression	Gastroesophageal Junction Adenocarcinoma	HER-2 expression	Gastroesophageal Junction Adenocarcinoma	KN026 Sensitive: C2 – Inclusion Criteria KN026 Sensitive : C2	KN026 Sensitive: C2 – Inclusion Criteria KN026 Sensitive : C2
HER-2 expression	Gastric Cancer	HER-2 expression	Gastric Cancer	KN026 Sensitive: C2 – Inclusion Criteria KN026 Sensitive : C2	KN026 Sensitive: C2 – Inclusion Criteria KN026 Sensitive : C2
HER-2 expression	HER2 Positive Breast Cancer	HER-2 expression	HER2 Positive Breast Cancer	ado-trastuzumab emtansine Sensitive: C3 – Early Trials ado-trastuzumab emtansine Sensitive : C3	ado-trastuzumab emtansine Sensitive: C3 – Early Trials ado-trastuzumab emtansine Sensitive : C3
HER-2 expression	Colorectal Cancer	HER-2 expression	Colorectal Cancer	trastuzumab + tucatinib Sensitive: C3 – Early Trials trastuzumab + tucatinib Sensitive : C3	trastuzumab + tucatinib Sensitive: C3 – Early Trials trastuzumab + tucatinib Sensitive : C3
HER-2 expression	Salivary Gland Cancer	HER-2 expression	Salivary Gland Cancer	ARX788 Sensitive: C3 – Early Trials ARX788 Sensitive : C3	ARX788 Sensitive: C3 – Early Trials ARX788 Sensitive : C3
HER-2 expression	Colorectal Cancer	HER-2 expression	Colorectal Cancer	ARX788 Sensitive: C3 – Early Trials ARX788 Sensitive : C3	ARX788 Sensitive: C3 – Early Trials ARX788 Sensitive : C3
HER-2 expression	Biliary Tract Cancer	HER-2 expression	Biliary Tract Cancer	ARX788 Sensitive: C3 – Early Trials ARX788 Sensitive : C3	ARX788 Sensitive: C3 – Early Trials ARX788 Sensitive : C3
HER-2 expression	Non Small Cell Lung Cancer	HER-2 expression	Non Small Cell Lung Cancer	ARX788 Sensitive: C3 – Early Trials ARX788 Sensitive : C3	ARX788 Sensitive: C3 – Early Trials ARX788 Sensitive : C3
HER-2 expression	Gastric Cancer	HER-2 expression	Gastric Cancer	ARX788 Sensitive: C3 – Early Trials ARX788 Sensitive : C3	ARX788 Sensitive: C3 – Early Trials ARX788 Sensitive : C3
HER-2 expression	Colorectal Cancer	HER-2 expression	Colorectal Cancer	panitumumab Resistant: C3 – Early Trials panitumumab Resistant : C3	panitumumab Resistant: C3 – Early Trials panitumumab Resistant : C3
HER-2 expression	HER2 Positive Breast Cancer	HER-2 expression	HER2 Positive Breast Cancer	nivolumab + fam-trastuzumab deruxtecan-nxki Sensitive: C3 – Early Trials nivolumab + fam-trastuzumab deruxtecan-nxki Sensitive : C3	nivolumab + fam-trastuzumab deruxtecan-nxki Sensitive: C3 – Early Trials nivolumab + fam-trastuzumab deruxtecan-nxki Sensitive : C3
HER-2 expression	Pancreatic Adenocarcinoma	HER-2 expression	Pancreatic Adenocarcinoma	trastuzumab + erlotinib + gemcitabine Sensitive: C3 – Early Trials trastuzumab + erlotinib + gemcitabine Sensitive : C3	trastuzumab + erlotinib + gemcitabine Sensitive: C3 – Early Trials trastuzumab + erlotinib + gemcitabine Sensitive : C3
HER-2 expression	Colorectal Cancer	HER-2 expression	Colorectal Cancer	trastuzumab + lapatinib Sensitive: C3 – Early Trials trastuzumab + lapatinib Sensitive : C3	trastuzumab + lapatinib Sensitive: C3 – Early Trials trastuzumab + lapatinib Sensitive : C3

HER-2 expression

Associations